Granted Patent
B2
US 12,320,799 · App. 17/720,067 · Granted Jun 3, 2025
Methods of measuring signaling pathway activity for selection of therapeutic agents
Assignee:
Celcuity Inc.
G01N33/5011A61K31/407A61K31/4709A61K31/4985A61K31/506A61K45/06G01N33/5044G01N33/57484G01N33/5017G01N33/5041G01N2333/71G01N2800/52G01N2800/7028
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Provided herein are methods for simultaneously determining the functional status of multiple signaling pathways in a diseased cell sample obtained from a subject to thereby select for therapeutic use in the subject a targeted therapeutic agent that affects the signaling pathway with the highest level of aberrant activity in the subject's cells. Also provided are methods for determining whether a signaling pathway is ultrasensitive in a diseased cell sample from a subject, also allowing for selection of an effective targeted therapeutic agent for therapeutic use in the subject. Methods of administering a selected targeted therapeutic agent to the subject are also provided.
Claims (25)
1. A method of treating a human subject diagnosed with cancer, the method comprising:
administering to the subject at least one targeted therapeutic that targets a signaling pathway selected from the group consisting of Protein kinase B (AKT), Phosphoinositide 3-kinase (PI3K), MAPK/ERK kinase (MEK), Extracellular signal-regulated kinase (ERK) and Mammalian target of rapamycin (mTOR), wherein
the at least one targeted therapeutic is therapeutically active in said signaling pathway in the subject's cancer cells by a method comprising:
culturing a sample comprising viable cancer cells obtained from the subject;
contacting the sample with at least one triplet set of agents, each triplet set comprised of a first agent targeted therapeutic and at least two second agent activators that are known to selectively affect the same signaling pathway the targeted therapeutic is intended to address, so as to upregulate or downregulate the signaling pathway as measured by an effect on cell adhesion or attachment, to produce a sample contacted with at least one triplet set of agents;
continuously measuring cell adhesion or attachment of the viable cancer cells in the sample contacted with the at least one triplet set of agents, relative to a sample of viable cancer cells obtained from the subject that is contacted with the first agent targeted therapeutic or each of the second agent activators alone;
determining an output value, expressed as a percentage, for the at least one triplet set of agents that characterizes whether a change in cell adhesion or attachment has occurred in the sample contacted with the triplet set of agents, as compared to the sample contacted with the first agent targeted therapeutic or the second agent activators alone; and
administering to the subject the at least one targeted therapeutic that affects the same signaling pathway as the first agent targeted therapeutic from the triplet set of agents when the output value percentage is greater than 50% indicating the targeted therapeutic is therapeutically active in the cell signaling pathway of the subject's cancer cells.
2. A method of treating a human subject diagnosed with cancer, the method comprising:
administering to the subject at least one targeted therapeutic that targets a signaling pathway selected from the group consisting of Protein kinase B (AKT), Phosphoinositide 3-kinase (PI3K), MAPK/ERK kinase (MEK), Extracellular signal-regulated kinase (ERK) and Mammalian target of rapamycin (mTOR), wherein
the at least one targeted therapeutic is therapeutically active in said signaling pathway in the subject's cancer cells by a method comprising:
culturing a sample comprising viable cancer cells obtained from the subject;
contacting the sample simultaneously with at least one triplet set of agents, each triplet set comprised of a first agent targeted therapeutic, a second agent activator that is known to selectively affect the same signaling pathway the first agent is intended to address and a third agent targeted therapeutic that affects a different signaling pathway than the first agent or a different location within the signaling pathway that the first agent affects, so as to upregulate or downregulate the signaling pathway that the first agent affects as measured by an effect on cell adhesion or attachment, to produce a sample contacted with at least one triplet set of agents;
continuously measuring cell adhesion or attachment of the viable cancer cells in the sample contacted with the at least one triplet set of agents, relative to a sample of viable cancer cells obtained from the subject that is contacted with the first agent targeted therapeutic alone, the second agent activator alone or the third agent targeted therapeutic alone;
determining an output value, expressed as a percentage, for the at least one triplet set of agents that characterizes whether a change in cell adhesion or attachment has occurred in the sample contacted with the triplet set of agents, as compared to the sample contacted with the first agent targeted therapeutic alone, the second agent activator alone or the third agent targeted therapeutic alone; and
administering to the subject the at least one targeted therapeutic that affects the same signaling pathway as the first agent targeted therapeutic from the triplet set of agents when the output value percentage is greater than 50% indicating the first agent targeted therapeutic agent is therapeutically active in the cell signaling pathway of the subject's cancer cells.
3. The method of claim 1 , which comprises contacting the sample with a targeted therapeutic that inhibits a PI3K or mTOR signaling pathway and with an activator of the PI3K or mTOR signaling pathway.
4. The method of claim 1 , wherein cell adhesion or attachment is measured using an impedance biosensor or an optical biosensor.
5. The method of claim 1 , wherein the cancer is selected from the group consisting of breast cancer, lung cancer, colorectal cancer, bladder cancer, kidney cancer, ovarian cancer and leukemia.
6. The method of claim 1 , wherein the targeted therapeutic that is administered to the subject is the first agent targeted therapeutic.
7. The method of claim 1 , wherein the targeted therapeutic that is administered to the subject is different than the first agent but targets the same signaling pathway as the first agent.
8. The method of claim 2 , wherein cell adhesion or attachment is measured using an impedance biosensor or an optical biosensor.
9. The method of claim 2 , wherein the cancer is selected from the group consisting of breast cancer, lung cancer, colorectal cancer, bladder cancer, kidney cancer, ovarian cancer and leukemia.
10. The method of claim 2 , wherein the targeted therapeutic that is administered to the subject is the first agent targeted therapeutic.
11. The method of claim 2 , wherein the targeted therapeutic that is administered to the subject is different than the first agent but targets the same signaling pathway as the first agent.
Assignments (3)
RELEASE OF SECURITY INTEREST
Recorded Jun 8, 2026
From: INNOVATUS LIFE SCIENCES LENDING FUND I, LP
To: CELCUITY INC.
Reel/Frame 074883/0538 →
AMENDED AND RESTATED INTELLECTUAL PROPERTY SECURITY AGREEMENT
Recorded May 30, 2024
From: CELCUITY, INC.
To: INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT
Reel/Frame 067572/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Apr 26, 2022
From: LAING, LANCE GAVIN; SULLIVAN, BRIAN FRANCIS
To: CELCUITY INC.
Reel/Frame 059733/0826 →
Continuity (5)
Continuation
PCTUS2018022936
· Mar 16, 2018
Provisional Application
62587572
· Nov 17, 2017
Provisional Application
62473936
· Mar 20, 2017
References Cited (231)
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 6041642A
· Duncan
· 2000
[cited by applicant]
US 6077684A
· Kravtsov
· 2000
[cited by applicant]
US 6258553B1
· Kravtsov
· 2001
[cited by applicant]
US 6331392B1
· Laing et al.
· 2001
[cited by applicant]
US 6372772B1
· Kirkpatrick et al.
· 2002
[cited by applicant]
US 6399078B1
· Devico et al.
· 2002
[cited by applicant]
US 6569628B2
· Laing et al.
· 2003
[cited by applicant]
US 6673596B1
· Sayler et al.
· 2004
[cited by applicant]
US 6974706B1
· Melker et al.
· 2005
[cited by applicant]
US 7192752B2
· Xu et al.
· 2007
[cited by applicant]
US 7429492B2
· Lin et al.
· 2008
[cited by applicant]
US 7459303B2
· Wang et al.
· 2008
[cited by applicant]
US 7468255B2
· Xu et al.
· 2008
[cited by applicant]
US 7470533B2
· Xu et al.
· 2008
[cited by applicant]
US 7560269B2
· Wang et al.
· 2009
[cited by applicant]
US 7592188B2
· Hahn et al.
· 2009
[cited by applicant]
US 7628085B2
· Laing et al.
· 2009
[cited by applicant]
US 7790406B2
· Cunningham et al.
· 2010
[cited by applicant]
US 7832291B2
· Laing et al.
· 2010
[cited by applicant]
US 7863052B2
· Schulz et al.
· 2011
[cited by applicant]
US 7927822B2
· Genick et al.
· 2011
[cited by applicant]
US 7960170B2
· Schulz et al.
· 2011
[cited by applicant]
US 8061220B2
· Laing et al.
· 2011
[cited by applicant]
US 8168568B1
· Mehta et al.
· 2012
[cited by applicant]
US 8202735B2
· Genick et al.
· 2012
[cited by applicant]
US 8257936B2
· Laing et al.
· 2012
[cited by applicant]
US 8298780B2
· Wagner et al.
· 2012
[cited by applicant]
US 9404915B2
· Laing et al.
· 2016
[cited by applicant]
US 20020031778A1
· Laing et al.
· 2002
[cited by applicant]
US 20030004140A1
· Dalton et al.
· 2003
[cited by applicant]
US 20030096275A1
· Laing
· 2003
[cited by applicant]
US 20030152992A1
· Laing et al.
· 2003
[cited by applicant]
US 20040084307A1
· Kim et al.
· 2004
[cited by applicant]
US 20040115713A1
· Laing
· 2004
[cited by applicant]
US 20040115786A1
· Laing
· 2004
[cited by applicant]
US 20050130321A1
· Nicholson et al.
· 2005
[cited by applicant]
US 20060003372A1
· Li et al.
· 2006
[cited by applicant]
US 20060141508A1
· Palmer
· 2006
[cited by applicant]
US 20060160109A1
· MacDonald et al.
· 2006
[cited by applicant]
US 20060275825A1
· Baird et al.
· 2006
[cited by applicant]
US 20060292581A1
· Laing
· 2006
[cited by applicant]
US 20070065415A1
· Kleinsek et al.
· 2007
[cited by applicant]
US 20080240543A1
· Budach et al.
· 2008
[cited by applicant]
US 20080299673A1
· Wagner et al.
· 2008
[cited by applicant]
US 20090192049A1
· Baird et al.
· 2009
[cited by applicant]
US 20100015721A1
· Laing
· 2010
[cited by applicant]
US 20100098166A1
· Budagavi et al.
· 2010
[cited by applicant]
US 20100143959A1
· Cunningham et al.
· 2010
[cited by applicant]
US 20100202923A1
· Cunningham et al.
· 2010
[cited by applicant]
US 20100291575A1
· Shamah et al.
· 2010
[cited by applicant]
US 20100329933A1
· Schulz et al.
· 2010
[cited by applicant]
US 20110130302A1
· Shen et al.
· 2011
[cited by applicant]
US 20110195047A1
· Aldabe Arregui et al.
· 2011
[cited by applicant]
US 20110231103A1
· Fang
· 2011
[cited by applicant]
US 20120022048A1
· Lori et al.
· 2012
[cited by applicant]
US 20120101230A1
· Wang et al.
· 2012
[cited by applicant]
US 20120107840A1
· Wagner et al.
· 2012
[cited by applicant]
US 20120237502A1
· Darnowski
· 2012
[cited by applicant]
US 20130210057A1
· Deng et al.
· 2013
[cited by applicant]
US 20130330761A1
· Laing et al.
· 2013
[cited by applicant]
US 20170343554A1
· Sullivan et al.
· 2017
[cited by applicant]
US 20210215673A1
· Laing et al.
· 2021
[cited by applicant]
US 20220412957A1
· Laing et al.
· 2022
[cited by applicant]
JP 2011514522A
· 2011
[cited by applicant]
JP 2012526992A
· 2012
[cited by applicant]
JP 2013543006A
· 2013
[cited by applicant]
JP 2015527055A
· 2015
[cited by applicant]
WO 03008530A2
· 2003
[cited by applicant]
WO 2006113747A2
· 2006
[cited by applicant]
WO 2006108183A2
· 2006
[cited by applicant]
WO 2007081779A2
· 2007
[cited by applicant]
WO 2009073916A1
· 2009
[cited by applicant]
WO 2009108637A1
· 2009
[cited by applicant]
WO 2010052225A1
· 2010
[cited by applicant]
WO 2010085845A1
· 2010
[cited by applicant]
WO 2010098166A1
· 2010
[cited by applicant]
WO 2010132723A1
· 2010
[cited by applicant]
WO 2012068435A1
· 2012
[cited by applicant]
WO 2012157647A1
· 2012
[cited by applicant]
WO 2013033623A1
· 2013
[cited by applicant]
WO 2013086301A1
· 2013
[cited by applicant]
WO 2013188500A1
· 2013
[cited by applicant]
WO 2014083178A1
· 2014
[cited by applicant]
WO 2015089380A2
· 2015
[cited by applicant]
WO 2016094904A1
· 2016
[cited by applicant]
WO 2018175251A1
· 2018
[cited by applicant]
Du Z. et al., “Mechanisms of receptor tyrosine kinase activation in cancer,” Molecular Cancer, vol. 17(1) 13 pages (2018).
[cited by applicant]
Extended European Search Report, European Application No. 21159001.3, dated Oct. 21, 2021, 14 pages.
[cited by applicant]
Gimple, R. et al., “RAS: Striking at the Core of the Oncogenic Circuitry,” Frontiers in Oncology, vol. 9 (2019).
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2020/063890, dated Feb. 18, 2022, 8 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2020/063890, dated Mar. 19, 2021, 25 pages.
[cited by applicant]
Rana, P. et al., “Efficacy and Tolerability of Lapatinib in the Management of Breast Cancer,” Breast Cancer: Basic Clinical Research, vol. 6:67-77 (2012).
[cited by applicant]
Abassi, Y., “Label-Free and Dynamic Monitoring of cell-Based Assays”, Cell Analysis, Biochemica, No. 2, 8-11 (2008).
[cited by applicant]
Ablin, R. J. et al., “Prostate Transglutaminase (TGase-4) Antagonizes the Anti-tumour Action of MDA-7/IL-24 in Prostate Cancer,” Journal of Translational Medicine, vol. 9 (49): 1-8 (2008).
[cited by applicant]
Aroui, S. et al., “Naringin suppresses cell metastasis and the expression of matrix metalloproteinases (MMP-2 and MMP-9) via the inhibition of ERK-P38-JNK signaling pathway in human glioblastoma,” Chemico-Biological Int…
[cited by applicant]
Arteaga, C. et al., “ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics,” Cancer Cell, vol. 25(3):282-303 (2014).
[cited by applicant]
Atienza, J. et al., “Label-free and real-time cell-based kinase assay for; screening selective and potent receptor tyrosine kinase inhibitors using microelectronic sensor array”, Journal of Biomolecular Screening, vol. …
[cited by applicant]
Bohunicky, B. et al., “Biosensors: the new wave in cancer diagnosis,” Nanotechnology, Science and Applications, vol. 4:1-10 (2010).
[cited by applicant]
Bosanquet, D. et al.,“Expression of IL-24 and IL-24 Receptors in Human Wound Tissues and the Biological Implications of IL-24 on Keratinocytes,” Wound Repair and Regeneration, vol. 20: 896-903 (2012).
[cited by applicant]
Brower, S. et al., “The ChemoFx® Assay: An Ex Vivo Chemosensitivity and Resistance Assay for Predicting Patient Response to Cancer Chemotherapy,” Methods in Molecular Biology, vol. 414: Apoptosis and Cancer, 57-78 (2007…
[cited by applicant]
Buck, E. et al., “Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition,” Mol Cancer Ther vol. 6(2):532-541(2007).
[cited by applicant]
Capuzzo, F., “The Human Epidermal growth factor Receptor (HER) family:structure and function,” Guide to Targeted Therapies: EGFR mutations in NSCLC, Chapter Two, Springer International Publishing Switzerland, 12 pages (…
[cited by applicant]
Chan, C-M et al., “Inhibitory Effects of Resveratrol on PDGF-BB-Induced Retinal Pigment Epithelial Cell Migration via PDGFR beta, PI3K/Akt and MAPK Pathways,” PLOS, vol. 9, Issue 2, 1-14 (2013).
[cited by applicant]
Chan, L. et al., “A label-free photonic crystal biosensor imaging method for detection of cancer cell cytotoxicity and proliferation,” Apoptosis, vol. 12:1061-1068 (2007).
[cited by applicant]
Chigaev, A. et al., “Galphas-coupled receptor signaling actively down-regulates alpha4beta1-integrin affmity: A possible mechanism for cell de-adhesion,” BMC Immunology, vol. 9(26):1-16 (2008).
[cited by applicant]
Choi, B-K., et al., “ERBB3 (HER3) is a key sensor in the regulation of ERBB-mediated signaling in both low and high ERBB2 (HER2) expressing cancer cells,” Cancer Medicine, vol. 1:28-38(2013).
[cited by applicant]
Cragg, M. et al, “Unleashing the power of inhibitors of oncogenic kinases through BH3 mi-metics,” Nature Reviews Cancer, vol. 9:321-326 (2009).
[cited by applicant]
Cunningham, B. et al., “Label-free assays on the BIND system,” Journal of Biomolecular Screening, vol. 9 (6):481-490). (2004).
[cited by applicant]
Davis et al, “Comprehensive analysis of kinase inhibitor selectivity,” Nature Biotechnology, vol. 29:(11)1046-1051 (2011).
[cited by applicant]
De Alava, E. et al., “Neuregulin expression modulates clinical response to trastuzumab in patients with metastatic breast cancer,” Journal of Clinical Oncology, vol. 25(19):2656-2663 (2007).
[cited by applicant]
Ekert J. E., et al., “Three-Dimensional Lung Tumor Microenvironment Modulates Therapeutic Compound Responsiveness In Vitro—Implication for Drug Development,” PLOS ONE, vol. 9 (3): 14 pages, e92248 (2014).
[cited by applicant]
Endo, H. et al., “Spheroid Culture of Primary Lung Cancer Cells with Neuregulin 1 /HER3 Pathway Activation,” Journal of Thoracic Oncology, vol. 8(2):131-139 (2013).
[cited by applicant]
European Examination Report, EP Application No. 13731594.1, dated Jun. 28, 2016, 11 pages.
[cited by applicant]
Extended European Search Report, European Application No. 18157442.7 dated Apr. 3, 2018, 10 pages.
[cited by applicant]
Extended European Search Report, European Application No. 19180662.9, dated Dec. 9, 2019, 10 pages.
[cited by applicant]
Extended European Search Report, European Application No. 20152262.0 , dated Jul. 1, 2020, 15 pages.
[cited by applicant]
Extended European Search Report, European Application No. 21159001.3, dated Jul. 14, 2021, 16 pages.
[cited by applicant]
Fang, Ye, “Label-Free and Nononvasive Biosensor Cellular Assays for Cell Adhesion,” Journal of Adhesion Science and Technology, vol. 24:1011-1021 (2010).
[cited by applicant]
Fountzilas, G. et al., “Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adj…
[cited by applicant]
Gharwan, H. et al. “Kinase inhibitors and monoclonal antibodies in oncology: clinical implications,” Nature Reviews Clinical Oncology, vol. 13:209-227 (2016).
[cited by applicant]
Gianni, L. et al., “Open-Label, Phase II, Multicenter, Randomized Study of the Efficacy and Safety of Two Dose Levels of Pertuzumab, a Human Epidermal Growth Factor Receptor 2 Dimerization Inhibitor, in Patients with Hu…
[cited by applicant]
Gilad, I. et al., “Insulin-like-growth-factor-I (IGF-I) antagonizes apoptosis induced by serum deficiency and doxorubicin in neuronal cell culture,” Growth Hormone & IGF Research, vol. 9: 458-464 (1999).
[cited by applicant]
Guerra, Y., et al., “Lack of efficacy of adjuvant lapatinib in HER2-negative breast cancer (HER2-ve BC): Analysis of patients in the TEACH trial,” 2013 ASCO Annual Meeting: Abstracts: Meeting Library, J. Clin. Oncol, vo…
[cited by applicant]
Hassan, S. et al., “Model for Time Dependency of Cytotoxic Effect of CHS 828 in Vitro Suggests Two Different Mechanisms of Action,” The Journal of Pharmacology and Experimental Therapeutics, vol. 299(3):1140-1147 (2001).
[cited by applicant]
Hermanto U. et al., “ErbB2-overexpressing human mammary carcinoma cells display an increased requirement for the phosphatidylinositol 3-kinase signaling pathway in anchorage-independent growth”, Oncogene, vol. 20 (51):7…
[cited by applicant]
Holt, R.U. et al., “Human myeloma cells adhere to fibronectin in response to hepatocyte growth factor,” Haematologica/The Hematology Journal, vol. 90(4):479-488. (2005).
[cited by applicant]
Howe, L. et al., “Targeting the HER/EGFR/ErbB Family to Prevent Breast Cancer,” Cancer Prev Res., vol. 4 (8):1149-1157 (2011).
[cited by applicant]
Huang, Y et al., “A functional signal profiling test for identifying a subset of HER2-negative breast cancers with abnormally amplified HER2 signaling activity,” OncoTarget, vol. 7(48):78577-78590 (2016) XP055474584, DO…
[cited by applicant]
Huang, Y., et al., “Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells,” BMC Cancer, vol. 17 (199):18 pages (2017) , XP055474590, DOI: 10.1186/s12885…
[cited by applicant]
Hughes & Siemann, “Have Clinical Trials Properly Assessed c-Met Inhibitors?” Trends in Cancer, vol. 4:94-97 (2018).
[cited by applicant]
Hynes, R., “Integrins: Bidirectional, Allosteric Signaling Machines,” Cell, vol. 110:673-687 (2002).
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2013/045338, dated Dec. 16, 2014, 8 pages.
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2015/065584, dated Jun. 13, 2017, 10 pages.
[cited by applicant]
International Preliminary Report on Patentability, PCT/US2018/022936, dated Sep. 24, 2019, 14 pages.
[cited by applicant]
International Preliminary Report on Patentability, PCTUS2014/069980, dated Jun. 14, 2016, 10 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2013/045338, dated Aug. 5, 2013, 12 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/2015/065584, dated Mar. 7, 2016, 15 pages.
[cited by applicant]
International Search Report and Written Opinion, PCT/US2018/022936, dated Jul. 19, 2018, 25 pages.
[cited by applicant]
International Search Report and Written Opinion, PCTUS2014/069980, dated Jun. 26, 2015, 18 pages.
[cited by applicant]
Invitation to Pay Additional Fees and, Where Applicable, Protest Fee, PCT/US2018/022936, dated May 24, 2018, 16 pages.
[cited by applicant]
Jonker, DJ et al., “Cetuximab for the treatment of colorectal cancer,” New England J of Med., vol. 357 (20):2040-2048 (2007).
[cited by applicant]
Kanakry, C., et al., “Neuregulin-1 regulates cell adhesion via an ErbB2/phosphoinositide-3 kinase/Akt-dependent pathway: potential implications for schizophrenia and cancer,” PLoS One, vol. 12:e1369: pp. 1-12 (2007).
[cited by applicant]
Wallasch, C. et al., “Heregulin-dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.,” EMBO Journal, vol. 14:4267-4275 (1995).
[cited by applicant]
Xi, B. et al., “The application of cell-based label-free technology in drug di scovery,” Biotechnology Journal, vol. 3 (4):484-495 (2008).
[cited by applicant]
Xia, W. et al., “Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways,” Oncogene, vol. 21(41):6255-6263 (2002).
[cited by applicant]
Yang, TY. et al., “A multiple reaction monitoring (MRM) method to detect Bcr-Abl kinase activity in CML using a peptide biosensor,” PLoS One, vol. 8, e56627, 10 pages (2013).
[cited by applicant]
Yuste, L. et al., “Activation of ErbB2 by Overexpression or by Transmembrane Neuregulin Results in Differential Signaling and Sensitivity to Herceptin,” Cancer Res., vol. 65 (15): 6801-6810 (2005).
[cited by applicant]
Zhao, W. et al, “Neuregulin 1 enhances cell adhesion molecule 11 expression in human glio-ma cells and promotes their migration as a function of malignancy,” J Neuropathol Exp Neu-rol., vol. 72(3):244-255 (2013).
[cited by applicant]
Kepp, O. et al., “Cell death assays for drug discovery,” Nature Reviews, vol. 10: 221-237 (2011).
[cited by applicant]
Kleinhans, R. et al., “Sensor-based cell and tissue screening for personalized cancer chemotherapy,” Med Biol Eng Comput, vol. 50(2):117-126 (2012).
[cited by applicant]
Konya, V. et al., “Endothelial E-type Prostanoid 4 Receptors Promote Barrier Function and Inhibit Neutrophil Trafficking,” J. Allergy Clin. Immunol., vol. 131(2), No. 2:532-540 (2013).
[cited by applicant]
Kwak, E. et al., “The Role of Irreversible HER Family Inhibition in the Treatment of Patients with Non-Small Cell Lung Cancer,” The Oncologist, vol. 16:1498-1507 (2011).
[cited by applicant]
Laing, L. et al., “Dynamic real-time signaling profiles of live primary cells characterize the response of PI3K and MAPK pathways in HER2+ breast cancer cells to attenuation with lapatinib: Tests of reproducibility of m…
[cited by applicant]
Laing, L. et al., “New method to measure functional HER2-driven signaling activity in primary tumor cells identifies HER2-negative breast cancers with abnormal HER2 signaling activity: New group of patients may benefit …
[cited by applicant]
Laing, L. et al., “New method to measure functional HER2-driven signaling activity in primary tumor cells identifies HER2-negative breast cancers with abnormal HER2 signaling activity: New group of patients may benefit …
[cited by applicant]
Laing, L. et al., “Use of a functional signal profiling test to determine the prevalence of abnormal HER2-driven signaling activity in the HER2-negative breast cancer patient population: New patient group may benefit fr…
[cited by applicant]
Laing, L. et al., “Use of a functional signal profiling test to determine the prevalence of abnormal HER2-driven signaling activity in the HER2-negative breast cancer patient population: New patient group may benefit fr…
[cited by applicant]
Laing, L., “Live tumor cell functional analysis and a xenograft model find co-activated c-Met and ErbB signaling in HER2-negative breast cancer,” 2018 American Society of Clinical Oncology (ASCO), J Clin Oncol., vol. 36…
[cited by applicant]
Laing, L., “Profiling of signaling pathways in live tumor cells to assess drug mechanism of action: A method to predict drug efficacy in a patient [e11583],” American Society of Clinical Oncologists 2014, Journal of Cli…
[cited by applicant]
Laing, L., “The Pulse of Label Free Indicates the Technology is Alive and Beating,” Drug Discovery, vol. 5: 24-30 (Oct./Nov. 2010).
[cited by applicant]
Laing, L., et al., “Inhibition of abnormal HER2-driven signaling by two HER2 targeted antibody drugs tested ex vivo in live primary HER2-breast cancer cell samples and HER2+ cell lines,” Abstract: #459, 2017 Miami Breas…
[cited by applicant]
Laing, L., et al., “Measuring functional HER2-driven signaling status ex vivo to predict response to HER2 therapy: Results from a mouse breast tumor xenograft study,” 2017 American Society of Clinical Oncology (ASCO), J…
[cited by applicant]
Laing, L., et al., “Quantification of HER2-driven signaling (HER2S) inhibition of four different anti-HER2 drugs tested ex vivo in live primary HER2-negative breast cancer cell samples with abnormal HER2 signaling activ…
[cited by applicant]
Lee, CY et al., “Neuregulin autocrine signaling promotes self-renewal of breast tumor-initiating cells by triggering HER2/HER3 activation,” Cancer Res., vol. 74(1):341-52 (2014).
[cited by applicant]
Levasseur, L. et al., “Modeling of the Time-Dependency of in Vitro Drug Cytotoxicity and Resistance,” Cancer Research, vol. 58(24):5749-5761 (1998).
[cited by applicant]
Liu Q. et al., “Impedance studies of bio-behavior and chemosensitivity of cancer cells by micro-electrode arrays,” Biosensors and Bioelctronics, Elsevier BV, NL, vol. 24 (5):1305-1310 (2009).
[cited by applicant]
Loum, E. et al., “Oncogramme, a new individualized tumor response testing method: application to colon cancer,” Cytotechnology, vol. 62:381-388 (2010).
[cited by applicant]
Lu, C. et al., “Effect of Epidermal Growth Factor Receptor Inhibitor on Development of Estrogen Receptor-Negative Mammary Tumors,” Journal of the National Cancer Institute, vol. 95(24):1825-1833 (2003).
[cited by applicant]
Mamounas, E., MD, MPH., et al., “A phase 2 study of neoadjuvant chemotherapy plus trastuzumab and pertuzumab in HER2-negative breast cancer patients with abnormal HER2-driven signaling transduction,” (NCT03412643) NSABP…
[cited by applicant]
Matsuo, T. et al., “Analysis of the anti-tumor effect of cetuximab using protein kinetics and mouse xenograft models,” BMC Research Notes, vol. 4(140):1-8.(2011).
[cited by applicant]
McGuinness, R et al., “Impedance-based cellular assay technologies: recent advances, future promise,” Current Opinion in Pharmacology, vol. 7(5):535-540 (2007).
[cited by applicant]
Menendez, J.A., et al., Trastuzumab in Combination With Heregulin-Activated Her-2 (erbB-2) Triggers a Receptor-Enhanced Chemosensitivity Effect in the Absence of Her-2 Overexpression, Journal of Clinical Oncology, vol. …
[cited by applicant]
Mestres, P. et al., “The Bionas technology for anticancer drug screening,” Expert Opinion Drug Discovery, vol. 4 (7):785-797 (2009).
[cited by applicant]
Moasser, M. “The oncogene HER2; Its signaling and transforming functions and its role in human cancer pathogenesis,” Oncogene, vol. 26(45):6469-6487 (2007).
[cited by applicant]
Montero, J. et al., “P-Rex1 participates in Neuregulin-ErbB signal transduction and its ex-pression correlates with patient outcome in breast cancer,” Oncogene, vol. 30(9):1059-1071 (2011).
[cited by applicant]
Morrison, S. et al., “Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains,” Proc. Natl. Acad. Sci. USA, vol. 81:6851-6855 (1984).
[cited by applicant]
Muise-Helmericks, R. et al., “Cyclin D Expression Is Controlled Post-transcriptionally via a Phosphatidylinositol 3-Kinase/Akt-dependent Pathway,” The Journal Of Biological Chemistry, vol. 273 (45):Issue of Nov. 6, 2986…
[cited by applicant]
Natarajan K. et al., “The Pim Kinase Inhibitor AZD1208 Enhances Apoptosis Induction By Clinically Active FLT3 Inhibitors in FLT3-ITD Acute Myeloid Leukemia Cells in Vitro and in Vivo through Synergistic Downregulation o…
[cited by applicant]
Niepel, M. et al., “Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines,” Science Signaling, vol. 6 (294): ra84, 12 pages (2013).
[cited by applicant]
Ochs, R. et al., “The ChemoFx.@ Assay an Ex Vivo Cell Culture Assay for Predicting Anticancer Drug Responses,” Methods in Molecular Medicine, vol. 110: Chemosensitivity: vol. 1: In Vitro Assays:155-172 (2005).
[cited by applicant]
Ona, T. et al., “Advanced dynamic monitoring of cellular status using label-free and non-invasive cell-based sensing technology for the prediction of anticancer drug efficacy,” Anal. Bioannal. Chem., vol. 398:2505-2533 …
[cited by applicant]
Otto, A. et al., “Microphysiological testing for chemosensitivity of living tumor cells with multiparametric microsensor chips,” Cancer Detection and Prevention, vol. 27:291-296 (2003).
[cited by applicant]
Otto, A. et al., “Multiparametric Sensor Chips for Chemosensitivity Testing of Sensitive and Resistant Tumor Cells,” Recent Results in Cancer Research, vol. 161:39-47 (2003).
[cited by applicant]
Park, J. et al., “Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development,” Clinical Cancer Research, vol. 10:3885-3893 (2004).
[cited by applicant]
Peters, M. et al., “Comparing Label-Free Biosensors for Pharmacological Screening with Cell-Based Functional Assays,” Assay and Drug Development Technolgoies, vol. 8(2):219-227 (2010).
[cited by applicant]
Ressler, J. et al , “New concepts for chip-supported multi-well-plates: realization of a 24-well-plate with integrated impedance-sensors for functional cellular screening applications and automated microscope aided cell…
[cited by applicant]
Schuler, M. et al., “A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer,” Breast Cancer Research and Treatment, vol. 134 (3):1149-11…
[cited by applicant]
Scott, C. et al., “Label-free whole-cell assays: expanding the scope of GPCR screening,” Drug Discovery Today, vol. 15,(17/18): 704-716(2010).
[cited by applicant]
Shamah, S et all., “Label-free cell-based assays using photonic crystal optical biosensors,” Analyst, vol. 136:1090-1102 (2011).
[cited by applicant]
Singer F. C. et al., “Predicting the efficacy of trastuzumab-based therapy in breast cancer: Current standards and future strategies,” Biochimica et Biophysica Acta Reviews on Cancer, vol. 1786:105-113 (2008).
[cited by applicant]
Solly, K. et al., “Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays,” Assay and Drug Development Technologies, vol. 2(4):363-372 (2004).
[cited by applicant]
Sprague, L. et al., “Multiparametric Sensor-Chip Based Technology for Monitoring Metabolic Activity: A Proof-of- Principle Study with Live Tissue,” Clin. Lab., vol. 52:375-384 (2006).
[cited by applicant]
Struber, M. et al., “Low-potassium Dextran Solution Ameliorates reperfusion injury of the lung and protects surfactant function,” The Journal of Thoracic and Cardiovascular Surgery, vol. 120(3):566-572 (2000).
[cited by applicant]
Summons to Oral Proceedings, European Application No. 18157442.7, dated Nov. 21, 2018, 11 pages.
[cited by applicant]
Sun, C. et al. “Feedback and redundancy in receptor tyrosine kinase signaling: relevance to cancer therapies,” Trends in Biochemical Sciences, vol. 39: 465-474 (2014).
[cited by applicant]
Tan, M. et al., “Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase,” Cancer Res., vol. 59(7):1620-1625 (1999).
[cited by applicant]
Tyson, J. et al., “Dynamic modelling of estrogen signalling and cell fate in breast cancer cells,” Nature Reviews, vol. 11(7):523-530 (2011).
[cited by applicant]
Unger F. et al., “Prediction of Individual Response to Anticancer Therapy: Historical and Future Perspectives,” Cell Mol. Life Science, vol. 72:729-757 (2015).
[cited by applicant]